Relapsing Refractory Multiple Myeloma Pipeline Drugs Assessment 2025: Advances in Research, Treatment Approaches, and Trials

DelveInsight's, "Relapsed/Refractory Multiple Myeloma Pipeline Insight, 2025" report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Relapsed/Refractory Multiple Myeloma pipeline landscape. It covers the Relapsing Refractory Multiple Myeloma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Relapsing Refractory Multiple Myeloma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight's comprehensive Relapsing Refractory Multiple Myeloma Pipeline Report to explore emerging therapies, key Companies, and future treatment landscapes @ Relapsing Refractory Multiple Myeloma Pipeline Outlook Report- https://www.delveinsight.com/sample-request/relapsing-refractory-multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Relapsing Refractory Multiple Myeloma Pipeline Report
• In August 2025, Bristol-Myers Squibb announced a study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM: SUCCESSOR-2.
• In August 2025, Celgene announced a study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have had prior lenalidomide exposure.
• In August 2025, Gracell Biotechnologies (Shanghai) Co., Ltd. announced a study is a single-arm, open-lable, phase I/II study to evaluate the efficacy and safety of GC012F in subjects with relapsed/refractory multiple myeloma.
• DelveInsight's Relapsing Refractory Multiple Myeloma pipeline report depicts a robust space with 55+ active players working to develop 60+ pipeline therapies for Relapsing Refractory Multiple Myeloma treatment.
• The leading Relapsing Refractory Multiple Myeloma Companies such as Bristol-Myers Squibb, I-MAB Biopharma, Pfizer, Arcellx, Gilead Sciences, Novartis, Array Biopharma, Hrain Biotechnology Co., Ltd., Cartesian Therapeutics, Xencor, Takeda, Sorrento Therapeutics, Heidelberg Pharma AG, Ichnos Sciences, Allogene Therapeutics, Harpoon Therapeutics, Cellectis, Poseida Therapeutics, Regeneron Pharmaceuticals, ONK Therapeutics, TeneoOne, iTeos Therapeutics, Oricell Therapeutics, Anaveon AG, Luminary Therapeutics, Seagen Inc., Trillium Therapeutics Inc., Virtuoso BINco, Inc. and others.
• Promising Relapsing Refractory Multiple Myeloma Pipeline Therapies such as Elranatamab, Venetoclax, Daratumumab, Carfilzomib, Pomalidomide, Bortezomib, LBH589 (panobinostat), ATG-010 and others.

Discover how the Relapsing Refractory Multiple Myeloma treatment paradigm is evolving. Access DelveInsight's in-depth Pipeline Analysis for a closer look at promising breakthroughs @ Relapsing Refractory Multiple Myeloma Clinical Trials and Studies- https://www.delveinsight.com/sample-request/relapsing-refractory-multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Relapsing Refractory Multiple Myeloma Emerging Drugs Profile

• Mezigdomide: Bristol-Myers Squibb
Cereblon E3 ligase modulators (CELMoD) are a class of oral immunomodulatory therapeutics that are designed to stimulate the immune system and directly kill cancer cells by inducing the degradation of tumor-promoting proteins. Bristol Myers Squibb is investigating two novel CELMoD agents, mezigdomide and iberdomide, for multiple myeloma that were intentionally designed to improve upon the demonstrated efficacy of the IMiD® agents, along with manageable tolerability, ease of administration, and the potential to improve patient outcomes. These agents co-opt cereblon to induce degradation of target proteins Ikaros and Aiolos, which inhibits tumor cell proliferation, promote tumor cell death, and induce immune-stimulatory effects. Mezigdomide induces maximal degradation of Ikaros and Aiolos, leading to increased apoptosis in myeloma cells. Based on Phase I/II interim results, mezigdomide, in combination with weekly DEX (40 mg; 20 mg if >75 years of age), showed promising efficacy in a highly refractory patient population. Mezigdomide is currently being investigated in Phase III stage of development for the treatment of Relapsed or Refractory Multiple Myeloma.

• Iopofosine: Cellectar Biosciences, Inc.
Iopofosine is a small-molecule Phospholipid Drug ConjugateTM designed to provide targeted delivery of iodine-131 (radioisotope) directly to cancer cells, while limiting exposure to healthy cells. We believe this profile differentiates iopofosine from many traditional on-market treatments. Iopofosine is currently being evaluated in the CLOVER-WaM Phase 2 pivotal study in patients with relapsed/refractory (r/r) Waldenstrom's macroglobulinemia (WM), a Phase 2b study in r/r multiple myeloma (MM) patients and the CLOVER-2 Phase 1 study for a variety of pediatric cancers. The U.S. Food and Drug Administration granted iopofosine Fast Track Designation for WM patients having received two or more prior treatment regimens, as well as r/r MM and r/r diffuse large B-cell lymphoma (DLBCL). Orphan Drug Designations (ODDs) have been granted for WM, MM, neuroblastoma, rhabdomyosarcoma, Ewing's sarcoma and osteosarcoma. Iopofosine was also granted Rare Pediatric Disease Designation (RPDD) for the treatment of neuroblastoma, rhabdomyosarcoma, Ewing's sarcoma and osteosarcoma. The European Commission granted an ODDs for r/r MM and WM.

• ORIC-533: ORIC Pharmaceuticals
ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens, being developed for multiple myeloma. Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Relapsed or Refractory Multiple Myeloma.

The Relapsing Refractory Multiple Myeloma Pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Relapsing Refractory Multiple Myeloma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Relapsing Refractory Multiple Myeloma Treatment.
• Relapsing Refractory Multiple Myeloma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Relapsing Refractory Multiple Myeloma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Relapsing Refractory Multiple Myeloma market.

Get a detailed analysis of the latest innovations in the Relapsing Refractory Multiple Myeloma pipeline. Explore DelveInsight's expert-driven report today! @ Relapsing Refractory Multiple Myeloma Unmet Needs- https://www.delveinsight.com/sample-request/relapsing-refractory-multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Relapsing Refractory Multiple Myeloma Companies
Bristol-Myers Squibb, I-MAB Biopharma, Pfizer, Arcellx, Gilead Sciences, Novartis, Array Biopharma, Hrain Biotechnology Co., Ltd., Cartesian Therapeutics, Xencor, Takeda, Sorrento Therapeutics, Heidelberg Pharma AG, Ichnos Sciences, Allogene Therapeutics, Harpoon Therapeutics, Cellectis, Poseida Therapeutics, Regeneron Pharmaceuticals, ONK Therapeutics, TeneoOne, iTeos Therapeutics, Oricell Therapeutics, Anaveon AG, Luminary Therapeutics, Seagen Inc., Trillium Therapeutics Inc., Virtuoso BINco, Inc. and others.

Relapsing Refractory Multiple Myeloma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Relapsing Refractory Multiple Myeloma Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule

Download DelveInsight's latest report to gain strategic insights into upcoming Relapsing Refractory Multiple Myeloma Therapies and key Developments @ Relapsing Refractory Multiple Myeloma Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/relapsing-refractory-multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Relapsing Refractory Multiple Myeloma Pipeline Report
• Coverage- Global
• Relapsing Refractory Multiple Myeloma Companies- Bristol-Myers Squibb, I-MAB Biopharma, Pfizer, Arcellx, Gilead Sciences, Novartis, Array Biopharma, Hrain Biotechnology Co., Ltd., Cartesian Therapeutics, Xencor, Takeda, Sorrento Therapeutics, Heidelberg Pharma AG, Ichnos Sciences, Allogene Therapeutics, Harpoon Therapeutics, Cellectis, Poseida Therapeutics, Regeneron Pharmaceuticals, ONK Therapeutics, TeneoOne, iTeos Therapeutics, Oricell Therapeutics, Anaveon AG, Luminary Therapeutics, Seagen Inc., Trillium Therapeutics Inc., Virtuoso BINco, Inc. and others.
• Relapsing Refractory Multiple Myeloma Pipeline Therapies- Elranatamab, Venetoclax, Daratumumab, Carfilzomib, Pomalidomide, Bortezomib, LBH589 (panobinostat), ATG-010 and others.
• Relapsing Refractory Multiple Myeloma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Relapsing Refractory Multiple Myeloma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Relapsing Refractory Multiple Myeloma drug development? Find out in DelveInsight's exclusive Pipeline Report-access it now! @ Relapsing Refractory Multiple Myeloma Emerging Drugs and Major Companies- https://www.delveinsight.com/sample-request/relapsing-refractory-multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.